STOCK TITAN

Avid Bioservices to Participate in RBC Capital Markets Virtual CDMO Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Avid Bioservices to participate in RBC Capital Markets Virtual CDMO Conference on October 2-3, 2023. Nick Green, CEO, will be the featured speaker in a fireside chat.
Positive
  • None.
Negative
  • None.

TUSTIN, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the RBC Capital Markets Virtual CDMO Conference. Nick Green, president and chief executive officer, will be the featured speaker in a fireside chat at the conference, which will take place October 2-3, 2023.

Details of the company’s participation are as follows:

  • RBC Capital Markets Virtual CDMO Conference
    Conference Date: October 2-3, 2023
    Fireside Chat Time/Date: 11:00 – 11:30 a.m. Eastern on Tuesday, October 3, 2023

About Avid Bioservices, Inc.  

Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 30 years of experience producing biologics, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com


Avid Bioservices, Inc.

NASDAQ:CDMO

CDMO Rankings

CDMO Latest News

CDMO Stock Data

516.73M
58.33M
1.1%
91.92%
15.99%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
TUSTIN

About CDMO

avid bioservices, a subsidiary of peregrine pharmaceuticals, inc. (nasdaq: pphm), is a unique contract manufacturing organization ("cmo") partner dedicated to the development and production of monoclonal antibodies, recombinant proteins and enzymes produced in mammalian cell culture. our extensive experience at all stages of development enables us to provide comprehensive development, manufacturing and support services to navigate a biologic from concept to commercialization.